Founder & Scientist – Dr Vanessa Craig
For more than a decade, Formettā founder and biomedical research doctor Vanessa Craig actively researched how inflammation and environmental factors influence gene activity and discovered how supplementing wisely could be the secret to improved health and graceful ageing.
«I did not set out to start a nutraceutical company, I created a product that wasn’t in the market that I was seeking for myself. I wanted my supplements to be in a single dose which is why I devolped Formettā»
«I did not set out to start a nutraceutical company, I created a product that wasn’t in the market that I was seeking for myself. I wanted my supplements to be in a single dose which is why I devolped Formettā»
The Formettā (difference) is backed by Dr Craig’s extensive education in her field
Her studies, research, and personal experience increased Dr. Craig’s fascination with the powers of collagen—prompting her to develop the formula for Formettā.
Dr. Craig began her studies at the University of Sydney, where she completed a BSc in Molecular Biology and Genetics, with Honours in Biochemistry. During these rigorous studies, Dr. Craig developed an interest in the effects of inflammation and environmental factors on our genes and the genetic legacy we transmit to the next generation. She graduated summa cum laude with a PhD in molecular oncology from the University of Zürich, where she also patented two targeted cancer therapies.
At the Novartis Institute of Biomedical Research, Dr. Craig was awarded a fellowship to continue her research in epigenetics and became interested in how nutrition, among other lifestyle factors, impacts our health and longevity. She studied Nutrition Science at the School of Medicine at Stanford University to sharpen her knowledge further and gain a more holistic understanding of the interplay between nutrition, ageing, and overall health.
Active ingredients in harmony
Dr. Craig capitalised on her scientific knowledge to pair bioactive collagen peptides with co-ingredients that slow the visible signs of ageing. Formulated with specifically-selected, well-studied components that replenish the body, fight damage from free radicals, and aid proper cell function, Formettā supports ageing gracefully and overall good health.
Dr Craig’s work extends beyond Formetta
Vanessa leads a personalised and evidence-based nutrition program at RIVR – a top-tier medical campus in Zurich. She uses blood biomarker profiling, DNA analysis and deep listening to achieve the precise health goals of her clients. The 360° approach considers all pillars of health and focuses on gentle behavioural changes.
| 2019 | Nutrition Science Course, Stanford University, Professor Christopher Gardner |
| 2016 | Founder and CEO at Formetta Gmbh, Zurich Switzerland. |
| 2014 | Drug discovery & development project simulation, Novartis Institute for Biomedical research (NIBR) |
| 2013 | Novartis leadership program, Novartis Institute for Biomedical research (NIBR) |
| 2012 | Presidential Postdoctoral Fellow, Novartis Institute for Biomedical research (NIBR) Basel, Switzerland. |
| 2011 | Postdoctoral Research Fellow, Group of Prof. Anne Müller, Institute of Molecular Cancer Research, University of Zürich, Switzerland |
| 2010 | Novartis Biotechnology Leadership Camp 2010 |
| 2009 | Scientific Ethics Course, Life Science Zürich Graduate School (ETH/University of Zürich) |
| 2008 | Molecular and Cell Biology of Cancer Course, Life Science Zürich Graduate School (ETH/University of Zürich) |
| 2008 | Clinical Cancer Research Course, Life Science Zürich Graduate School (ETH/ University of Zürich) |
| 2008 | Laboratory Animal Science Course, Life Science Zürich Graduate School (ETH/ University of Zürich) |
| 2007 | PhD in Cancer Biology, Group of Prof. Anne Müller, University of Zürich, Switzerland. |
| 2007 | Life Science Zurich Graduate School, ETH |University Zurich Member of the Cancer Biology PhD Program |
| 2006 | Research Associate, Group of Prof. Jacqui Matthews, School of Molecular Biosciences, University of Sydney, Australia |
| 2006 | Honours in Biochemistry, Group of Prof. Jacqui Matthews, School of Molecular Biosciences, University of Sydney, Australia |
| 2002 | BSc Molecular Biology and Genetics, University of Sydney, Australia |
- Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C*, Craig VJ* et al (2017) Leukemia. doi: 10.1038/leu.2016.327
*equal contributing authors - Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth.
Harbinski F*, Craig VJ* et al (2012) Cancer Discovery. 2012 Sep 26.
*equal contributing authors - Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B- cell lymphoma in vivo.
Craig VJ, Tzankov A, Flori M, Schmid C A, Bader AG and Müller A. (2012) Leukemia. doi: 10.1038/leu.2012.110. - Epigenetic silencing of miRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis.
Craig VJ, Cogliatti SB, Rehrauer H, Wündisch T and Müller A. (2011) Cancer Research. 71(10):3616-24. - Myc-mediated repression of microRNA-34a promotes high grade transformation of gastric B-cell lymphoma by dysregulation of FoxP1.
Craig VJ, Cogliatti SB, Neuenschwander S, Rehrauer H, Schlapbach R, Wündisch T, Tzankov A, Dirnhofer S and Müller A. (2011).
Blood. 117(23):6227-36. - B-cell receptor signaling and CD40 ligand-independent T-cell help cooperate in Helicobacter-induced MALT lymphomagenesis.
Craig VJ, Cogliatti SB, Arnold I, Gerke C, Balanda JE, Wündisch T, Müller A. (2010). Leukemia. 24, 1186-96. - Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins.
Craig VJ, Arnold I, Gerke C., Huynh MQ, Wundisch T, Neubauer A, Renner C, Falkow S, Mueller A. (2010). Blood. 115(3):581-591. - Competition between LIM binding domains.
Matthews JM, Bhati M, Craig VJ, Deane JE, Lee C, Nancarrow AL, Ryan DP, Sunde M. (2008) Biochem Soc Trans. Dec 36;(6): 1393-7 - Implementing the LIM code: the structural basis for cell type-specific assembly of LIM-homeodomain complexes.
Bhati M, Lee C, Nancarrow AL, Lee M, Craig VJ, Bach I, Guss JM, Mackay JP, Matthews JM. (2008)
EMBO J. Jul 23;27(14):2018-29. - Treatment of ABL1 overexpressing B-cell lymphoma. Craig VJ and Müller A.
World Intellectual Property Publication: WO 2012/041959 A1, 5th April 2012 - Treatment of B-cell lymphoma with microRNA. Craig VJ and Müller A.
World Intellectual Property Publication: WO2012/035131 A1, 22nd March 2012